2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
376
Polycystic Ovary Syndrome
41
Neoplasm Metastasis
23
Endometrial Neoplasms
22
Ovarian Neoplasms
16
Neoplasms
14
Infertility
12
Advanced Breast Cancer
10
Fallopian Tube Neoplasms
8
Carcinoma, Intraductal, Noninfiltrating
8
Triple Negative Breast Neoplasms
7
Recurrence
7
Osteoporosis
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Breast Diseases
7
Carcinoma, Lobular
6
Breast Carcinoma In Situ
6
Prostatic Neoplasms
5
Leiomyoma
4
Infertility, Female
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Arthralgia
4
Obesity
3
Neoplasms, Hormone-Dependent
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Anovulation
3
Uterine Neoplasms
2
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Drug Therapy
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Mitomycin
3
Docetaxel
3
Cetuximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Letrozole
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled